Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

1.755 +0.065 (+3.85%)
Streaming Delayed Price Updated: 9:55 AM EDT, Mar 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Coherus Oncology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Coherus Oncology Inc (NASDAQ:CHRS) Reports Mixed Q4 2025 Results as LOQTORZI Sales Grow ↗
Via Chartmill
News headline image
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology to Participate in Upcoming Investor Conferences
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
Coherus BioSciences's Earnings Outlook ↗
 
Via Benzinga
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock
From Coherus Oncology, Inc.
Via GlobeNewswire
These stocks have an unusual volume in today's session ↗
Via Chartmill
What's going on in today's session ↗
Via Chartmill
Which stocks are moving on Friday? ↗
Via Chartmill
The market is filled with gapping stocks in Friday's session. ↗
Via Chartmill
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma
-6 Years Long-term survival data reinforce potential benefit to patient survival in treating recurrent or metastatic nasopharyngeal carcinoma with LOQTORZI in combination with chemotherapy - 
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology to Participate in Upcoming Investor Conferences
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals ↗
4 biotech stocks—ALDX, ALEC, BDTX, CHRS—show strong week-on-week momentum ranking gains and improving technical indicators. 
Via Benzinga
News headline image
Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
– CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in SITC’s upcoming webinar series “Targets for Cancer IO: A Deep Dive” on October 22, 2025 – 
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗
 
Via Benzinga
News headline image
Coherus Oncology to Participate in Upcoming Investor Conferences
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus (CHRS) Q2 Revenue Jumps 10% ↗
Via The Motley Fool
News headline image
Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
From Coherus Oncology, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.